Vividion Therapeutics, Inc. (Vividion), a clinical-stage biopharmaceutical company known for its novel discovery technologies targeting high-value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, announced plans to expand its global innovation capabilities. The company will establish a new research and development (R&D) center and corporate headquarters in San Diego, California. Vividion operates as a wholly owned, independently operating subsidiary of Bayer AG.
The new facility will enhance Vividion’s R&D capabilities, significantly increasing the company’s chemoproteomics screening capacity. More than half of the space will be dedicated to state-of-the-art research labs, supporting the advancement of Vividion’s clinical and preclinical programs as well as future discovery efforts. This expansion will also enable the company to attract and retain top life sciences talent in San Diego, a rapidly growing biotech innovation hub.
“Vividion is entering an exciting new phase with multiple programs in clinical trials, a robust discovery portfolio, and extensive platform screening efforts aimed at bringing previously undruggable disease targets within reach of small molecule therapeutics,” said Aleksandra Rizo, M.D., Ph.D., CEO of Vividion. “Our new R&D center and headquarters will provide the infrastructure to execute our strategic vision and continue leading the way in applying chemoproteomics and covalent chemistry to create first-in-class medicines for patients in need. Our culture of innovation, driven by outstanding people working collaboratively, will thrive in our new state-of-the-art home.”
“Vividion is a key component of Bayer’s innovation strategy, focused on bringing first-in-class medicines to market to address unmet medical needs,” said Stefan Oelrich, Member of the Board of Management of Bayer AG and President Pharmaceuticals at Bayer. “This new facility will support our strategic growth opportunities, enabling the company to capitalize on the rich array of drug discovery and clinical development opportunities offered by its pioneering chemoproteomics platform.”
Bayer’s strategy for sustainable long-term growth includes rebuilding its portfolio, enhancing R&D capabilities, and reallocating resources, with a commitment to strengthening its presence in the United States. San Diego’s renowned biotech cluster, home to numerous life science companies and research institutes, offers a promising ecosystem for Bayer to bolster its leadership and innovation pipeline. Bayer has also established local presences in other major U.S. life science hubs, including Boston, San Francisco, and Research Triangle Park, North Carolina.
